Massive Transfusion Product Order
During massive transfusion, administer blood products simultaneously in a balanced ratio of at least 1:1:2 (FFP:Platelets:pRBC), with early tranexamic acid administration and continuous correction of coagulopathy guided by laboratory and viscoelastic monitoring.
Initial Resuscitation Strategy
The most current European trauma guideline 1 specifies that initial coagulation resuscitation should comprise either:
- Fibrinogen concentrate or cryoprecipitate PLUS packed red blood cells (pRBC), OR
- Fresh frozen plasma (FFP) or pathogen-inactivated FFP in a FFP:pRBC ratio of at least 1:2
A high platelet:pRBC ratio should also be applied from the outset 1.
Specific Product Ratios
For trauma patients specifically, use high-ratio transfusion strategies with at least one unit plasma per two units of packed red blood cells (1:2 FFP:pRBC minimum) 2. The 2024 Australian guideline recommends no fewer than 4 units FFP and 1 adult platelet unit for every 8 units pRBC 3, which translates to a 1:1:2 ratio.
The evidence shows that ratios ranging from 1:1:1 to 1:1:2 (FFP:Platelets:pRBC) are associated with mortality benefits in observational trauma data, though RCT evidence shows no significant difference between 1:1:1 and 1:1:2 ratios 2.
Critical Early Interventions
Tranexamic Acid - First Priority
Administer tranexamic acid immediately - this takes precedence and should not await laboratory results 1:
- 1 gram IV over 10 minutes as soon as possible (en route to hospital if feasible)
- Followed by 1 gram IV infusion over 8 hours
- Must be given within 3 hours of bleeding onset for trauma and obstetric hemorrhage 1, 3
Fibrinogen Supplementation
Initial fibrinogen dose of 3-4 grams (equivalent to 15-20 single donor cryoprecipitate units or fibrinogen concentrate) may be administered early 1. Repeat doses should be guided by viscoelastic monitoring and/or laboratory fibrinogen levels.
Goal-Directed Continuation
After initial balanced resuscitation, transition to goal-directed therapy using:
Laboratory Targets
- FFP: Use when PT/aPTT >1.5 times normal or viscoelastic evidence of coagulation factor deficiency 1
- Platelets: Maintain >50 × 10⁹/L (>100 × 10⁹/L in traumatic brain injury) 1
- Initial dose: 4-8 single platelet units or one apheresis pack
- Fibrinogen: Supplement when functional levels are low based on viscoelastic or laboratory assessment 1
- Calcium: Monitor ionized calcium frequently and maintain within normal range using calcium chloride 1
Additional Factor Concentrates
- Prothrombin complex concentrate (PCC) may be administered based on viscoelastic evidence of delayed coagulation initiation when fibrinogen levels are normal 1
- Factor XIII monitoring may be included with supplementation in bleeding patients with functional deficiency 1
Critical Pitfalls to Avoid
- Do NOT delay tranexamic acid for laboratory results - give immediately if massive transfusion is anticipated 1
- Do NOT use FFP solely for hypofibrinogenemia correction - use cryoprecipitate or fibrinogen concentrate instead 1
- Do NOT use recombinant activated factor VII (rFVIIa) routinely - only consider off-label if all other measures fail 1, 3
- Do NOT forget temperature, pH, and calcium - correct hypothermia, acidosis, and hypocalcemia continuously as these impair coagulation 1
Context-Specific Considerations
For non-traumatic massive bleeding: The evidence is weaker, with no specific recommendation for fixed high-ratio strategies 2. However, the balanced approach remains reasonable given the lack of harm demonstrated and potential benefits.
Obstetric hemorrhage: Similar principles apply with tranexamic acid within 3 hours 3, though actual product ratios may vary based on etiology (atony vs. placenta accreta) and individual response 4.
The key is early activation of massive transfusion protocols, immediate balanced product delivery, and rapid transition to laboratory-guided individualized therapy once initial resuscitation is underway 1, 3.